Neurodevelopmental benefits of antiretroviral therapy in ugandan children aged 0-6 years with HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 3, 2014, Pages 316-322

  Brahmbhatt, Heena ^a,b   Boivin, Michael ^c   Ssempijja, Victor ^b   Kigozi, Godfrey ^b   Kagaayi, Joseph ^b   Serwadda, David ^b,d   Gray, Ronald H ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

ARTs; HIV; HIV affected children; HIV infected children; Neurodevelopment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE;

AGE; ANTIVIRAL THERAPY; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD DEVELOPMENT; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; DISABILITY SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LANGUAGE; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MATERNAL CARE; MOTOR PERFORMANCE; NERVOUS SYSTEM DEVELOPMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTIVE FIELD; REFERENCE VALUE; TIME TO TREATMENT; TREATMENT DURATION; UGANDAN; VERTICAL TRANSMISSION; VISUAL ACUITY; ADULT; HIV INFECTIONS; INFANT; MIDDLE AGED; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; SERODIAGNOSIS; SPEECH; STATISTICAL MODEL; UGANDA; VISION;

ADULT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COGNITION; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; INFANT; INFANT, NEWBORN; LINEAR MODELS; MALE; MIDDLE AGED; MOTOR SKILLS; PROSPECTIVE STUDIES; SPEECH; UGANDA; VISUAL PERCEPTION;

EID: 84922016370     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000295     Document Type: Conference Paper

References (42)

1. Walker SP, Wachs TD, Gardner JM, et al. Child development: risk factors for adverse outcomes in developing countries. Lancet. 2007; 369:145-157.
2. Grantham-McGregor S, Cheung YB, Cueto S, et al. Developmental potential in the first 5 years for children in developing countries. Lancet. 2007;369:60-70.
3. Engle PL, Black MM, Behrman JR, et al. Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world. Lancet. 2007;369:229-242.
4. IOM. Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World. Washington, DC: National Academy Press; 2001.
5. Blanchette N, Smith ML, Fernandes-Penney A, et al. Cognitive and motor development in children with vertically transmitted HIV infection. Brain Cogn. 2001;46:50-53.
6. Epstein LG, Sharer LR, Oleske JM, et al. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics. 1986; 78:678-687.
7. Boivin MJ, Green SD, Davies AG, et al. A preliminary evaluation of the cognitive and motor effects of pediatric HIV infection in Zairian children. Health Psychol. 1995;14:13-21.
8. Drotar D, Olness K, Wiznitzer M, et al. Neurodevelopmental outcomes of Ugandan infants with human immunodeficiency virus type 1 infection. Pediatrics. 1997;100:E5.
9. Blanchette N, Smith ML, King S, et al. Cognitive development in schoolage children with vertically transmitted HIV infection. Dev Neuropsychol. 2002;21:223-241.
10. Tardieu M, Mayaux MJ, Seibel N, et al. Cognitive assessment of schoolage children infected with maternally transmitted human immunodeficiency virus type 1. J Pediatr. 1995;126:375-379.
11. Msellati P, Lepage P, Hitimana DG, et al. Neurodevelopmental testing of children born to human immunodeficiency virus type 1 seropositive and seronegative mothers: a prospective cohort study in Kigali, Rwanda. Pediatrics. 1993;92:843-848.
12. Nozyce M, Hittelman J, Muenz L, et al. Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life. Pediatrics. 1994; 94:883-891.
13. Abubakar A, Van Baar A, Van de Vijver FJR, Holding P, Newton CRJC. Cognitive assessment of human immunodeficiency virus-exposed children. Am J Dis Child. 1992;146:1479-1483.
14. Belman A. HIV-1 infection and AIDS. Neurol Clin. 2002;20:983-1011.
15. Sherr L, Mueller J, Varrall R. A systematic review of cognitive development and child human immunodeficiency virus infection. Psychol Health Med. 2009;14:387-404.
16. Bagenda D, Nassali A, Kalyesubula I, et al. Health, neurologic, and cognitive status of HIV-infected, long-surviving, and antiretroviralnaive Ugandan children. Pediatrics. 2006;117:729-740.
17. Abubakar A, Van BA, Van d V, et al. Paediatric HIV and neurodevelopment in sub-Saharan Africa: a systematic review. Trop Med Int Health. 2008;13:880-887.
18. McGrath N, Fawzi WW, Bellinger D, et al. The timing of mother-to-child transmission of human immunodeficiency virus infection and the neurodevelopment of children in Tanzania. Pediatr Infect Dis J. 2006;25:47-52.
19. Raskino C, Pearson DA, Baker CJ, et al. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virusinfected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics. 1999;104:e32.
20. Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS. 2012;26: 1685-1690.
21. Van RA, Dow A, Mupuala A, et al. Neurodevelopmental trajectory of HIV-infected children accessing care in Kinshasa, Democratic Republic of Congo. J Acquir Immune Defic Syndr. 2009;52: 636-642.
22. Van RA, Harrington PR, Dow A, et al. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol. 2007;11:1-9.
23. Kagaayi J, Dreyfuss ML, Kigozi G, et al. Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda. J Acquir Immune Defic Syndr. 2005;39:121-124.
24. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet. 1999; 353:525-535.
25. Gray RH, Wabwire-Mangen F, Kigozi G, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol. 2001;185:1209-1217.
26. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Geneva, Switzerland: WHO; 2010.
27. Durkin MS, Wang W, Shrout PE, et al. Evaluating a ten questions screen for childhood disability: reliability and internal structure in different cultures. J Clin Epidemiol. 1995;48:657-666.
28. Mullen EM. Mullen Scales of Early Learning: AGS Edition. Circle Pines, MN: American Guidance Services, Inc; 1995. Ref Type: Serial (Book, Monograph).
29. John CC, Bangirana P, Byarugaba J, et al. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics. 2008;122: e92-e99.
30. Boivin MJ, Bangirana P, Byarugaba J, et al. Cognitive impairment after cerebral malaria in children: a prospective study. Pediatrics. 2007;119: e360-e366.
31. Ultmann MH, Diamond GW, Ruff HA, et al. Developmental abnormalities in children with acquired immunodeficiency syndrome (AIDS): a follow-up study. Int J Neurosci. 1987;32:661-667.
32. Ensoli F, Wang H, Fiorelli V. HIV-1 infection and the developing nervous system: lineage-specific regulation of viral gene expression and replication in distinct neuronal precursors. J Neurovirol. 1997;3(4):290-298.
33. George R, Andronikou S, du Plessis J, du Plessis AM, Van Toorn R, Maydell A. Central nervous system manifestations of HIV infection in children. Pediatr Radiol. 2009;39:575-585.
34. Rice ML, Buchanan AL, Siberry GK, et al. Language impairment in children perinatally infected with HIV compared to children who were HIV-exposed and uninfected. J Dev Behav Pediatr. 2012;33: 112-123.
35. Rice ML, Zeldow B, Siberry GK, et al. Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants. Pediatr Infect Dis J. 2013;32: e406-e413.
36. Coplan J, Contello KA, Cunningham CK, et al. Early language development in children exposed to or infected with human immunodeficiency virus. Pediatrics. 1998;102:e8.
37. Wolters PL, Brouwers P, Civitello L, et al. Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24-month follow-up study. AIDS. 1997;11:1135-1144.
38. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
39. Smith L, Adnams C, Eley B. Neurological and neurocognitive function of HIV-infected children commenced on antiretroviral therapy. S Afr J Child Health 2008;2:108-113.
40. Lindsey JC, Malee KM, Brouwers P, et al. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007;119:e681-e693.
41. Puthanakit T, Ananworanich J, Vonthanak S, et al. Cognitive function and neurodevelopmental outcomes in HIV-infected children older than 1 Year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J. 2013;32: 501-508.
42. Boivin MJ, Bangirana P, Nakasujja N, et al. A year-long caregiver training program to improve neurocognition in preschool Ugandan HIV-exposed children. J Dev Behav Pediatr. 2013;34: 269-278.